More Information Product Details Synonyms Product Type Properties Formula MW CAS Purity Chemicals Appearance Solubility Identity Declaration Other Product Data InChi Key Shipping and Handling Shipping Short Term Storage Long Term Storage Handling Advice Use/Stability Documents MSDS Product Specification Sheet Datasheet

(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; ICI 46474; Istubal; Kessar; Noltam; Nolvadex; TMX; Valodex; Zemide

Chemical

C26H29NO . C6H8O7

563.64

54965-24-1

≥98%

White powder.

Soluble in DMSO or methanol. Slightly soluble in ethanol.

Determined by NMR.

Manufactured by Chemodex.

Click here for Original Manufacturer Product DatasheetOur product description may differ slightly from the original manufacturers product datasheet.

FQZYTYWMLGAPFJ-OQKDUQJOSA-N

AMBIENT

+20°C

+4°C

Keep cool and dry.Protect from light and moisture.

Stable for at least 2 years after receipt when stored at +4°C.

No

Download PDF

Selective estrogen receptor modulator (SERM) used as adjuvant therapy for estrogen-dependent breast cancer. Antagonist of ER action in breast tissue and breast cancer cells and ER agonist in bone, uterus, and the cardiovasculature system. This prodrug is metabolized by cytochrome P450 (CYP450) enzymes to the active metabolites N-desmethyl-TMX, 4-hydroxy-N-desmethyl-TMX (endoxifen) and 4-hydroxy-TMX (afimoxifene). N,N-Didesmethyl-4-hydroxytamoxifen (norendoxifen), another active metabolite has been found to act as a potent competitive aromatase inhibitor and may also be involved in its antiestrogenic activity. Binds microsomal antiestrogen binding sites, altering cholesterol esterification at therapeutic doses and impacting breast cancer cell differentiation, apoptosis, and autophagy. Protein kinase C (PKC) inhibitor and anti-angiogenetic factor.Product References(1) K. B. Horwitz & W. L. McGuire; J. Biol. Chem. 253, 8185 (1978) | (2) V.C. Jordan, et al.; Cancer Treat. Rep. 64, 745 (1980) | (3) C.A. OBrian, et al.; Cancer Res. 45, 2462 (1985) | (4) K.J. Edwards, et al.; J. Med. Chem. 35, 2753 (1992) | (5) M. Clarke, et al.; Lancet 351, 1451 (1998) | (6) D.A. Tonetti & V.C. Jordan; Mol. Med. Today 2, 218 (1996) | (7) J.M. Hall, et al.; J. Biol. Chem. 276, 36869 (2001) | (8) P. Thomas, et al.; Endocrinol. 146, 624 (2005) | (9) M.S. Singh, et al.; Breast 20, 111 (2011) | (10) P. de Medina, et al.; Chem. Phys. Lip. 164, 432 (2011) | (11) V.K. Todorova, et al.; Cancer Chemother. Pharmacol. 67, 285 (2011)